Axsome Therapeutics Inc. (AXSM) had a rough trading day for Thursday December 05 as shares tumbled 8.83%, or a loss of $-4.19 per share, to close at $43.24. After opening the day at $44.49, shares of Axsome Therapeutics Inc. traded as high as $46.00 and as low as $42.60. Volume was 1.6 million shares over 14,340 trades, against an average daily volume of n/a shares and a total float of 34.51 million.
As a result of the decline, Axsome Therapeutics Inc. now has a market cap of $1.49 billion. In the last year, shares of Axsome Therapeutics Inc. have traded between a range of $47.68 and $1.94, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Axsome Therapeutics Inc is a United States-based healthcare service provider. As a pre-clinical therapeutics developer, the company attends primarily to central nervous system disorders such as Alzheimer’s. Its product portfolio consists of novel drugs like the AXS-02 (disodium zoledronate tetrahydrate), which is an oral, non-opioid therapeutic for chronic pain and the AXS-05, which is a fixed-dose combination of dextromethorphan and bupropion. The AXS-02 addresses pain in over three conditions, such as complex regional pain syndrome, knee osteoarthritis and chronic low back pain. The AXS-05 on the other hand, treats resistant depression and agitation in patients with Alzheimer’s disease. Both the products have passed the preclinical, Phase 1 and Phase 2 stages of development.
Axsome Therapeutics Inc. is based out of New York, NY and has some 41 employees. Its CEO is Herriot Tabuteau.
Axsome Therapeutics Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
